AX-2026-041993
MOTS-c · 5 mg declared · AmbioPharm, Inc. · lot AMB-2601-N5360
- Report ID
- AX-2026-041993
- Compound
- MOTS-c
- Compound class
- Metabolic and mitochondrial peptides
- Supplier
- AMB — AmbioPharm, Inc.
- Batch / lot
- AMB-2601-N5360
- Declared label claim
- 5mg
- Laboratory
- Nordanalyt Laboratories
- Assay date
- 27 Jan 2026
- Submitted
- 01 Feb 2026
- Quarter
- 2026-Q1
- Submitter
- i.trevino
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the metabolic and mitochondrial peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 35 min gradient, 214 nm | 99.70 | % area | ≥ 98.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.30 | % area | ≤ 2.0 | PASS |
| Largest single impurity | RP-HPLC — Met1 sulfoxide (+16 Da) | 0.19 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 2173.0918 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 2173.0898 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -0.9 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 89.00 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 88.73 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 5.52 | mg | 5 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 4.898 | mg | 5 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 98.0 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 4.35 | % | ≤ 9.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 5.80 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.85 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | membrane filtration, USP <71>, 14 d | No growth at 14 d | — | no growth | PASS |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 5.66 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 35 min gradient | 12.05 | min | 12.02 ± 0.30 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.02 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 57,781 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs des-Met1 (−131 Da) | 1.25 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | MOTS-c — main peak | 12.05 | 4,845,729 | 99.70 | — |
| 2 | Met1 sulfoxide (+16 Da) | 11.61 | 9,235 | 0.19 | +15.995 |
| 3 | bis-sulfoxide (+32 Da) | 11.28 | 2,430 | 0.05 | +31.990 |
| 4 | deamidated (+1 Da) | 11.70 | 1,944 | 0.04 | +0.984 |
| 5 | des-Met1 (−131 Da) | 12.31 | 972 | 0.02 | -131.040 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 2173.0918 Da, computed from C101H152N28O22S2. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 4+ | 544.2802 | 544.2797 | -0.0005 | 7.8 |
| 3+ | 725.3712 | 725.3705 | -0.0007 | 52.8 |
| 2+ | 1087.5532 | 1087.5522 | -0.0010 | 100.0 |
| 1+ | 2174.0991 | 2174.0971 | -0.0020 | 56.9 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 4.35 |
| Counter-ion (acetate) | ion chromatography | 5.80 |
| Residual solvent + inorganic residue | estimated | 0.85 |
| Total peptide content | by difference | 89.00 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.90 | 99.70 | divergence +0.33 pp vs batch median |
| Total impurities (% area) | 0.10 | 0.30 | |
| Largest single impurity (% area) | 0.07 | 0.19 | |
| Water (%) | 2.7 | 4.35 | |
| Counter-ion (%) | not stated | 5.80 | |
| Peptide content (%w/w) | 92.5 | 89.00 | |
| Endotoxin (EU/mg) | 0.50 | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (−20 °C, 20 d) → laboratory (courier, dry ice, 8 d) → assay.
- Assay date
- 27 Jan 2026
- Submitted to the index
- 01 Feb 2026
- Laboratory
- Nordanalyt Laboratories, Uppsala, Sweden
- Method basis
- 35 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations 3
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot AMB-2601-N5360 n=2
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041994 | AMB-2601-N5360 | Nordanalyt | 2026-Q1 | 99.43 | 5.13 | — | Buyer-sourced | 0 | PASS |
Cross-sections
- All MOTS-c records n=105
- All AMB records n=203
- All Nordanalyt records n=545
- All 2026-Q1 records n=806
- MOTS-c by supplier
- MOTS-c impurity profile
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042083 | HYB | HYB-2606-D7858 | Medutest | 2026-Q3 | 99.93 | 2.02 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042090 | HYB | HYB-2606-D7858 | Janoshik | 2026-Q3 | 99.57 | 2.36 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-042084 | HYB | HYB-2606-D7858 | Janoshik | 2026-Q3 | 99.28 | 2.79 | 107.3 | Buyer-sourced | 0 | PASS |
| AX-2026-042087 | HYB | HYB-2606-D7858 | Janoshik | 2026-Q3 | 99.54 | 3.05 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042085 | HYB | HYB-2606-D7858 | Janoshik | 2026-Q3 | 99.51 | 2.31 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042088 | HYB | HYB-2606-D7858 | PeptideMeter | 2026-Q3 | 99.22 | 2.21 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042086 | HYB | HYB-2606-D7858 | Janoshik | 2026-Q3 | 99.93 | 3.02 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042081 | HYB | HYB-2606-D7858 | Nordanalyt | 2026-Q3 | 99.68 | 3.31 | 96.5 | Laboratory-retained | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042002 | Semaglutide | AMB-2607-N6274 | VendorInvestigate | 2026-Q3 | 98.23 | 6.37 | 97.1 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042012 | GHRP-6 | AMB-2603-S5667 | Janoshik | 2026-Q3 | 99.37 | 5.90 | 88.8 | Laboratory-retained | 1 | MARGINAL |
| AX-2026-041974 | Tirzepatide | AMB-2603-C5112 | Nordanalyt | 2026-Q3 | 98.20 | 3.41 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041975 | Tirzepatide | AMB-2603-C5112 | Medutest | 2026-Q3 | 97.88 | 3.45 | 106.9 | Laboratory-retained | 0 | PASS |
| AX-2026-042005 | Semaglutide | AMB-2607-N6274 | PeptideMeter | 2026-Q3 | 98.09 | 6.48 | 98.6 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042008 | Epitalon | AMB-2602-Y6433 | Janoshik | 2026-Q3 | 99.30 | 8.75 | 105.1 | Buyer-sourced | 0 | PASS |
| AX-2026-042021 | TB-500 | AMB-2602-P5987 | VendorInvestigate | 2026-Q3 | 99.86 | 4.79 | 101.4 | Buyer-sourced | 0 | PASS |
| AX-2026-042015 | GHRP-6 | AMB-2603-S5667 | Janoshik | 2026-Q3 | 99.54 | 6.44 | 97.1 | Buyer-sourced | 0 | PASS |